Moderna and Merck are preparing to launch the first ever phase three trial of a messenger RNA cancer vaccine, after a smaller study showed it boosted patients’ chances of surviving an aggressive type of skin cancer.
莫德纳(Moderna)和默克(Merck)正准备启动信使RNA(mRNA)癌症疫苗的首个3期试验，此前一项规模较小的研究表明，该疫苗提高了一种侵袭性皮肤癌的患者的存活几率。
您已阅读8%（302字），剩余92%（3611字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。